Winchester, VA – April 2026: StageBio Lead Scientist Brian Tabb has received the 2026 NSH President’s Award for outstanding leadership in histotechnology. Learn more about this honor!

StageBio is proud to announce that Brian Tabb, Lead Scientist on the investigative and molecular pathology team, has been named the recipient of the 2026 President's Award by the National Society for Histotechnology (NSH).

The President's Award is one of the most distinguished honors NSH bestows, recognizing an individual whose extraordinary service and professional commitment have made a lasting impact on the organization. Brian was selected in recognition of his long-standing dedication to the NSH Program Team, his leadership in advancing the society's poster program, and his unwavering commitment to excellence, including through periods of personal challenge.

"Brian's recognition by NSH is a reflection of the character and dedication he brings to everything he does, both here at StageBio and within the broader histotechnology community," said David Bruning, CEO of StageBio. "We are incredibly proud to have him on our team and congratulate him on this well-deserved honor."

Brian will be formally recognized at the 2026 NSH Histotechnology Convention, taking place September 25 to 29 in San Antonio, Texas. The award was announced during Lab Week (April 19 to 25), a national celebration honoring laboratory professionals across the country.

At StageBio, Brian leads scientific efforts on the investigative and molecular side of the business, contributing to the company's mission of delivering high-quality, scientifically rigorous preclinical pathology services. His expertise and leadership continue to strengthen StageBio's capabilities and reputation within the field.

About StageBio

StageBio is a leading provider of preclinical histology, pathology, and molecular services supporting drug development. With deep scientific expertise and a commitment to quality, StageBio partners with pharmaceutical and biotech clients to advance research from discovery through IND-enabling studies.